Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Assets (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Non-Current Assets readings, the most recent being $7.8 million for Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 77.55% to $7.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $39.7 million, a 78.51% decrease, with the full-year FY2025 number at $8.0 million, down 81.85% from a year prior.
  • Non-Current Assets hit $7.8 million in Q1 2026 for Atara Biotherapeutics, down from $8.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $89.1 million in Q2 2022 to a low of $7.8 million in Q1 2026.
  • Median Non-Current Assets over the past 5 years was $58.8 million (2024), compared with a mean of $53.4 million.
  • Biggest five-year swings in Non-Current Assets: dropped 2.59% in 2022 and later plummeted 81.85% in 2025.
  • Atara Biotherapeutics' Non-Current Assets stood at $81.3 million in 2022, then dropped by 21.77% to $63.6 million in 2023, then tumbled by 30.54% to $44.2 million in 2024, then plummeted by 81.85% to $8.0 million in 2025, then fell by 2.48% to $7.8 million in 2026.
  • The last three reported values for Non-Current Assets were $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $11.7 million (Q3 2025) per Business Quant data.